PMA device
FoundationOne CDx
Foundation Medicine, Inc. · Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP, Class III) · First FDA decision Nov 30, 2017, newest Sep 16, 2026Cancer detection and genomic testing
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
41
PMA pathway
Device trials
0
Naming "FoundationOne CDx"
MAUDE reports
0
Brand "FoundationOne CDx", since 2015
PubMed studies
303
Mentioning "FoundationOne CDx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing FoundationOne CDx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 41 decisions filed under this name.
- FoundationOne CDxPMA supplement
P170019-S069 · Decided Sep 16, 2026 · 180 days after receipt · Normal 180 Day Track No User Fee
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- FoundationOne CDxPMA supplement
P170019-S067 · Decided May 12, 2026 · 302 days after receipt · Normal 180 Day Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- FoundationOne CDxPMA supplement
P170019-S065 · Decided May 27, 2026 · 476 days after receipt · Normal 180 Day Track No User Fee
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: P170019-S058, P170019-S057, P170019-S054, P170019-S050, P170019-S048, P170019-S046, P170019-S045, P170019-S044, P170019-S043, P170019-S042, P170019-S040, P170019-S037, P170019-S036, P170019-S035, P170019-S034, P170019-S032, P170019-S030, P170019-S029, P170019-S028, P170019-S026, P170019-S025, P170019-S023, P170019-S021, P170019-S017, P170019-S016, P170019-S015, P170019-S014, P170019-S013, P170019-S011, P170019-S010, P170019-S008, P170019-S006, P170019-S005, P170019-S004, P170019
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40210Palmetto GBAUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40278WPS Insurance CorporationUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40226CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40222Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40278WPS Insurance CorporationUpdated Sep 15, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40222Noridian Healthcare Solutions, LLCUpdated Aug 22, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40226CGS Administrators, LLCUpdated Aug 21, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40210Palmetto GBAUpdated Aug 18, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "FoundationOne CDx", any status and sponsor, newest update first.
No registered device study names "FoundationOne CDx".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "FoundationOne CDx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PQP
14 reports: 11 malfunction, 2 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Hamilton Microlab STAR Liquid Handler; Protocol Configuration Tool (PCT) v2.0.0. Used to conduct F1CDx and F1LCDx.Open, Classified
Z-2951-2026 · Started Jun 10, 2026 · Posted by FDA Aug 14, 2026
Reason given: Software issue that can cause an increase in spontaneous software closures.
Cause as FDA categorized it: Software design · Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
Z-1937-2026 · Started Mar 24, 2026 · Posted by FDA Apr 23, 2026
Reason given: Potential for spontaneous closures of Hamilton HxRunControl software during execution of Autolys protocols after deployment of the PCT software for AutoLys Hamilton STAR.
Cause as FDA categorized it: Software change control · Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
- Sequencing Agent SEQ0067, component of FoundationOne CDx (F1CDx)Open, Classified
Z-1927-2026 · Started Mar 20, 2026 · Posted by FDA Apr 22, 2026
Reason given: Possible increase in phasing, potentially resulting in false-positive BARD1 splice site indel artifact variants
Cause as FDA categorized it: Under Investigation by firm · Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
6 more recall records with a free account
Published research
The most relevant PubMed records for "FoundationOne CDx"[tiab]. The summary above synthesizes these.
- FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity.
Honecker J, Paffenholz D, Jungmann J, et al. · J Mol Diagn · 2025
- FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience.
Kimura R, Ohtsuka T, Kubo M, et al. · Surg Today · 2021
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A, Fakih M, Lopez J, et al. · Lancet Oncol · 2020Clinical Trial, Phase II, Multicenter Study
- Genomic landscape of pleural and peritoneal mesothelioma tumours.
Hiltbrunner S, Fleischmann Z, Sokol ES, et al. · Br J Cancer · 2022Research Support, Non-U.S. Gov't
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Hellmann MD, Ciuleanu TE, Pluzanski A, et al. · N Engl J Med · 2018Clinical Trial, Phase III, Multicenter Study
- Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M, Takahama T, Sakai K, et al. · Oncologist · 2021Research Support, Non-U.S. Gov't
- Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
Milbury CA, Creeden J, Yip WK, et al. · PLoS One · 2022Research Support, Non-U.S. Gov't
- FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma.
Takahashi H, Ogino H, Bando H, et al. · Respir Med Case Rep · 2023Case Reports
- Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment.
Shah B, Hussain M, Seth A · Curr Issues Mol Biol · 2025Review
- FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas.
Sharaf R, Pavlick DC, Frampton GM, et al. · Neurooncol Adv · 2021
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
McGrail DJ, Pilié PG, Rashid NU, et al. · Ann Oncol · 2021Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.
Schenker M, Burotto M, Richardet M, et al. · J Immunother Cancer · 2024Clinical Trial, Phase II, Randomized Controlled Trial
Other devices of this type
Also filed under product code PQP.
- FoundationOne Liquid CDxFoundation Medicine, Inc. · PMA 2026
- Oncomine Dx Target TestLife Technologies Corporation · PMA 2025
- Guardant360 CDxGuardant Health, Inc. · PMA 2026
- Oncomine Dx Express TestLife Technologies Corporation · PMA 2026
- xT CDxTempus AI, Inc. · PMA 2026
- TruSight Oncology ComprehensiveIllumina, Inc. · PMA 2026
- FoundationOne®Liquid CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOneCDx (F1CDx)Foundation Medicine, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.